Literature DB >> 30848500

Identifying UBA2 as a proliferation and cell cycle regulator in lung cancer A549 cells.

Biying Jiang1, Xiaoxi Fan2, Di Zhang1, Haifeng Liu1, Chuifeng Fan1.   

Abstract

Ubiquitin activating enzyme 2 (UBA2) is a basic component of E1-activating enzyme in the SUMOylation system. Expression and function of UBA2 in human cancers are largely unknown. In this study we investigate UBA2 expression the function in human non-small-cell lung cancer. Immunochemistry study showed that UBA2 was overexpressed in cancer tissues (53.3%, 40 of 75) compared with normal lung tissues (14.3%, 4 of 28) (P < 0.05). Immunostaining of UBA2 was mainly detected in nucleus. Overexpression of UBA2 in cancer tissues was significantly associated with poor differentiation, large tumor size ( > 5.0 cm), higher T stages (T3 + 4), lymph node metastasis and advanced TNM stages (III + IV). In vitro study showed that UBA2 was expressed in A549, 95D, H1975, and H1299 cells. Knockdown of UBA2 in A549 cells significantly inhibited cancer cell proliferation and upregulated cancer cell apoptosis (P < 0.05). Cell cycle analysis showed that knockdown of UBA2 in A549 cell significantly increased the G1 and G2/M phase cells and reduced the S phase cells (P < 0.05). Gene expression profile after knockdown of UBA2 in A549 cells showed that the most related function was cell cycle, cell death and survival, and cellular growth and proliferation. Western blot analysis study showed that knockdown of UBA2 significantly inhibited expression of poly(ADP-ribose) polymerase 1, mini-chromosome maintenance 7 (MCM7), MCM2, MCM3 and MCM7. These results indicated that UBA2 was a critical cell cycle and proliferation regulator and may be a novel cancer marker in this malignant tumor.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  cell cycle; non-small-cell lung cancer; proliferation; ubiquitin activating enzyme 2

Mesh:

Substances:

Year:  2019        PMID: 30848500     DOI: 10.1002/jcb.28543

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  7 in total

1.  Bioinformatics-based analysis of SUMOylation-related genes in hepatocellular carcinoma reveals a role of upregulated SAE1 in promoting cell proliferation.

Authors:  Yang Liu; Xiang Wang; Xingzhi Zeng; Yinghua Wu; Xinrong Liu; Juan Tan; Xiaoyan Li
Journal:  Open Med (Wars)       Date:  2022-07-06

2.  CircRNA circ_0008037 facilitates tumor growth and the Warburg effect via upregulating NUCKS1 by binding to miR-433-3p in non-small cell lung cancer.

Authors:  Jia Yu; Haining Zhang; Chunsheng Zhao; Guanghui Li; Yingying Zhang; Yang Sun
Journal:  Thorac Cancer       Date:  2021-12-01       Impact factor: 3.500

3.  Knockdown of ubiquitin-like modifier-activating enzyme 2 promotes apoptosis of clear cell renal cell carcinoma cells.

Authors:  Guoxi Zhang; Junrong Zou; Jinglin Shi; Biao Qian; Kaiyang Qiu; Quanliang Liu; Tianpeng Xie; Zhihua He; Hui Xu; Yunfeng Liao; Yuting Wu; Yanmin Li; Guancheng Xiao; Yuanhu Yuan; Rihai Xiao; Gengqing Wu; Xiaofeng Zou
Journal:  Cell Death Dis       Date:  2021-11-09       Impact factor: 8.469

4.  Lung adenocarcinoma-derived vWF promotes tumor metastasis by regulating PHKG1-mediated glycogen metabolism.

Authors:  Jiayi Gu; Yingxue Qi; Yuxin Lu; Qianying Tao; Die Yu; Chunchun Jiang; Jianwen Liu; Xin Liang
Journal:  Cancer Sci       Date:  2022-02-20       Impact factor: 6.716

5.  WTIP upregulates FOXO3a and induces apoptosis through PUMA in acute myeloid leukemia.

Authors:  Yunqi Zhu; Xiangmin Tong; Ying Wang; Xiaoya Lu
Journal:  Cell Death Dis       Date:  2021-12-20       Impact factor: 8.469

6.  High expression of eukaryotic initiation factor 3M predicts poor prognosis in colon adenocarcinoma patients.

Authors:  Qing-Hua Wang; Min Zhang; Ming-Hui Zhou; Xiao-Jiao Gao; Fang Chen; Xun Yan; Feng Lu
Journal:  Oncol Lett       Date:  2019-11-29       Impact factor: 2.967

Review 7.  Novel insights into the impact of the SUMOylation pathway in hematological malignancies (Review).

Authors:  Ling Wang; Jinjun Qian; Ye Yang; Chunyan Gu
Journal:  Int J Oncol       Date:  2021-08-09       Impact factor: 5.650

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.